Canine Cancer × Gene × Drug Reference — Which Mutations Have Matching Targeted Drugs
The table gives directions; the evidence tier gives proportion
The value of sequencing is to say in advance "which mutations this cancer type commonly carries and which drugs they point to" — but every case must defer to the actual test result.
The "Cancer × Gene × Drug" reference for canine tumor gene testing answers three questions: which driver mutations does this cancer type commonly carry? Which drug directions do these mutations point to? How trustworthy are those directions? It provides directions and proportion — not prescriptions. Each case defers to the actual test report, and drug use is decided by a licensed veterinarian with evidence tier and clinical judgment.
Cancer × Gene × Drug reference table
| Cancer type | Common genes | Drug direction | Evidence tier |
|---|---|---|---|
| Mast cell tumor | c-KIT (reported mutation rate 9–45%) | KIT inhibitor class | A (strong canine) |
| GIST | c-Kit (confirm by IHC) | Targeted drug class | A–B |
| Transitional cell carcinoma (TCC) | BRAF | BRAF inhibitor class | B–C |
| Hemangiosarcoma | TP53 (~40%), PIK3CA (~17%) | Pathway direction (e.g., mTOR) | C (comparative) |
| Other solid / treatment-resistant tumors | Highly heterogeneous (some >4 genetic profiles) | Depends on test results | Per report |
Drug classes above are category illustrations (e.g., "KIT inhibitor class") and are not prescriptions. Variant frequencies come from published studies (human–canine cross-species and canine research); they may be updated as research evolves. More cancer types are added continuously.
A–D evidence tiers: how to read this table
- Tier A (strong canine evidence): e.g., c-KIT in mast cell tumors — solid canine clinical evidence; most credible direction
- Tier B (moderate canine evidence): e.g., c-Kit in GIST — canine studies exist; evidence accumulating
- Tier C (comparative oncology): e.g., TP53/PIK3CA in hemangiosarcoma — extrapolated from human tumors and pathway mechanisms; auxiliary
- Tier D (exploratory): frontier directions; limited reference value
The earlier the tier, the stronger the canine clinical support. Human data is auxiliary only — it does not equal a canine-approved indication, nor does it guarantee drug efficacy.
Why human data matters
Canine tumors are not carbon copies of human tumors, but at the molecular level they are highly homologous — canine driver genes are shared extensively with the corresponding human cancer types. Human treatment experience therefore points directions:
- Human–canine concordant prognostic genes: a real-world study of 2,119 dogs found strong concordance of prognostic genes (TP53, PIK3CA, NRAS, ATM, KIT) between human and canine tumors (npj Precision Oncology, 2023)
- A concrete example: after EGFR-targeted drug resistance, patients with the T790M mutation who switched to a third-generation drug had a 61% benefit rate versus 21% for T790M-negative patients (AURA3 trial; human lung-cancer data, for illustration only; see the handbook reference list)
This is the logic of comparative oncology (Tier C): look at how the homologous human cancer is treated, then confirm it against canine molecular evidence.
No matching row: the norm, not the exception
The reference table covers "high-frequency shared mutations" — but individual mutations vary endlessly, and most dogs' mutations fall outside the coverage of marketed targeted drugs. This is not bad luck; it is the norm: drug manufacturers only develop drugs for mutations shared by many patients.
No off-the-shelf key does not mean no path:
- Try with drug sensitivity testing: 3D organoid "avatars" directly measure the actual killing rate of 48 drugs — theory aside, it measures what really works (learn more)
- Teach with mRNA immunotherapy: personalized mRNA targets "this dog's own typos" — it does not need to share mutations with anyone (learn more)
- Targeted therapy walks the "population route", immunotherapy the "individual route", sensitivity testing measures "actual efficacy" — three complementary paths, each with its own role
Sequencing service is coming soon
Add us on WeChat: petcura to reserve a launch notification — we will contact you as soon as the service goes live; existing blocks can be submitted directly.
Learn more: Sequencing & Targeted Drug Guidance · Drug sensitivity testing · mRNA immunotherapy IIT · Sequencing FAQ